Executives from Aquestive Therapeutics (NASDAQ:AQST) said the U.S. Food and Drug Administration has issued a complete response letter (CRL) for the company’s New Drug Application for Anaphylm, an epinephrine sublingual film being developed for the treatment of anaphylaxis, requiring additional…